Stroke Unit and Division of Internal and Cardiovascular Medicine, Santa Maria della Misericordia Hospital, University of Perugia, Via G. Dottori 1, 06100, Perugia, Italy,
J Neurol. 2015 Feb;262(2):459-68. doi: 10.1007/s00415-014-7550-1. Epub 2014 Dec 2.
The aim of the ICARO-3 study was to evaluate whether intra-arterial treatment, compared to intravenous thrombolysis, increases the rate of favourable functional outcome at 3 months in acute ischemic stroke and extracranial ICA occlusion. ICARO-3 was a non-randomized therapeutic trial that performed a non-blind assessment of outcomes using retrospective data collected prospectively from 37 centres in 7 countries. Patients treated with endovascular treatment within 6 h from stroke onset (cases) were matched with patients treated with intravenous thrombolysis within 4.5 h from symptom onset (controls). Patients receiving either intravenous or endovascular therapy were included among the cases. The efficacy outcome was disability at 90 days assessed by the modified Rankin Scale (mRS), dichotomized as favourable (score of 0-2) or unfavourable (score of 3-6). Safety outcomes were death and any intracranial bleeding. Included in the analysis were 324 cases and 324 controls: 105 cases (32.4 %) had a favourable outcome as compared with 89 controls (27.4 %) [adjusted odds ratio (OR) 1.25, 95 % confidence interval (CI) 0.88-1.79, p = 0.1]. In the adjusted analysis, treatment with intra-arterial procedures was significantly associated with a reduction of mortality (OR 0.61, 95 % CI 0.40-0.93, p = 0.022). The rates of patients with severe disability or death (mRS 5-6) were similar in cases and controls (30.5 versus 32.4 %, p = 0.67). For the ordinal analysis, adjusted for age, sex, NIHSS, presence of diabetes mellitus and atrial fibrillation, the common odds ratio was 1.15 (95 % IC 0.86-1.54), p = 0.33. There were more cases of intracranial bleeding (37.0 versus 17.3 %, p = 0.0001) in the intra-arterial procedure group than in the intravenous group. After the exclusion of the 135 cases treated with the combination of I.V. thrombolysis and I.A. procedures, 67/189 of those treated with I.A. procedures (35.3 %) had a favourable outcome, compared to 89/324 of those treated with I.V. thrombolysis (27.4 %) (adjusted OR 1.75, 95 % CI 1.00-3.03, p = 0.05). Endovascular treatment of patients with acute ICA occlusion did not result in a better functional outcome than treatment with intravenous thrombolysis, but was associated with a higher rate of intracranial bleeding. Overall mortality was significantly reduced in patients treated with endovascular treatment but the rates of patients with severe disability or death were similar. When excluding all patients treated with the combination of I.V. thrombolysis and I.A. procedures, a potential benefit of I.A. treatment alone compared to I.V. thrombolysis was observed.
ICARO-3 研究的目的是评估与静脉溶栓相比,在急性缺血性脑卒中伴颅外颈内动脉闭塞患者中,动脉内治疗是否能提高 3 个月时的功能结局良好率。ICARO-3 是一项非随机治疗试验,使用前瞻性收集的来自 7 个国家 37 个中心的数据进行了非盲结局评估。在发病后 6 小时内接受血管内治疗的患者(病例)与在症状发作后 4.5 小时内接受静脉溶栓治疗的患者(对照组)进行匹配。在病例中包括接受静脉或血管内治疗的患者。使用改良 Rankin 量表(mRS)评估 90 天残疾结局,分为有利(评分 0-2)或不利(评分 3-6)。安全性结局是死亡和任何颅内出血。分析纳入了 324 例病例和 324 例对照组:105 例(32.4%)有良好结局,而 89 例对照组(27.4%)[校正比值比(OR)1.25,95%置信区间(CI)0.88-1.79,p=0.1]。在调整分析中,动脉内治疗与死亡率降低显著相关(OR 0.61,95%CI 0.40-0.93,p=0.022)。病例组和对照组严重残疾或死亡(mRS 5-6)的患者比例相似(30.5%与 32.4%,p=0.67)。对于因年龄、性别、NIHSS、糖尿病和心房颤动而进行的有序分析,共同的比值比为 1.15(95%CI 0.86-1.54),p=0.33。动脉内治疗组颅内出血发生率(37.0%)高于静脉组(17.3%)(p=0.0001)。排除 135 例接受静脉溶栓和动脉内治疗联合治疗的病例后,189 例接受动脉内治疗的病例中有 67 例(35.3%)有良好结局,而 324 例接受静脉溶栓治疗的病例中有 89 例(27.4%)(校正 OR 1.75,95%CI 1.00-3.03,p=0.05)。急性颈内动脉闭塞患者的血管内治疗并未导致比静脉溶栓更好的功能结局,但与更高的颅内出血发生率相关。接受血管内治疗的患者整体死亡率显著降低,但严重残疾或死亡的患者比例相似。当排除所有接受静脉溶栓和动脉内治疗联合治疗的患者后,观察到动脉内治疗与静脉溶栓相比有潜在的获益。